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The mTORC1 complex is required for glomerular function. (A) Schematic illustration of the generation of podocyte-specific Raptor-deficient 
(RaptorΔpodocyte) mice to interrupt mTORC1 signaling. (B) Western blot analysis of isolated glomeruli from RaptorΔpodocyte and control littermates. (C) 
Densitometric analysis confirmed significant reduction of glomerular Raptor and pS6 levels and an upregulation of pAkt T308 (n = 3 each; *P < 0.05). 
(D) 40-week follow-up of RaptorΔpodocyte mice for proteinuria and (E) body weight (n = 9 control, n = 10 RaptorΔpodocyte male mice; *P < 0.05; 
**P < 0.01). (F) RaptorΔpodocyte mice displayed an increased mortality after 40 weeks of age. Data are expressed as the mean ± SEM.
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Podocyte-specific deletion of the mTORC1 complex results in progressive glomerulosclerosis. (A and B) RaptorΔpodocyte mice developed pro-
gressive glomerulosclerosis between 2 and 12 months of age. Asterisks in photographs indicate proteinaceous casts in dilated tubules. Arrows 
indicate glomerulosclerosis with synechia formation (n = 4 mice each; *P < 0.05). Data are expressed as the mean ± SEM. (C and D) TEM 
analyses identified foot process effacement (arrows) at 4 and 12 months of age. (E) SEM analysis of foot processes at 12 months of age. Scale 
bars: 20 μm (A); 2 μm (C and D, upper panel); 1 μm (C and D, lower panel); 10 μm (E, first and third scanning electron micrograph); 1 μm 
(E, second and fourth scanning electron micrograph).
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Time-dependent deletion of Raptor indicates the importance of mTORC1 


























































































Time-specific deletion of Raptor indicates the importance of mTORC1 
activity during glomerular development. (A) Schematic illustration of 
the generation of doxycycline-inducible podocyte-specific Raptor-defi-
cient mice. (B) Western blot analysis of isolated glomeruli confirmed 
Raptor deletion after embryonic or adult doxycycline induction. (C) 
Densitometric analysis (n = 3 each; *P < 0.05). (D) Embryonic and 
adult doxycycline induction of mT/mG;NPHS2.rtTA;tetO.Cre reporter 
mice resulted in podocyte-specific GFP expression. Arrow indicates 
incomplete GFP expression in podocytes after adult induction. (E) Uri-
nary albumin excretion rates after embryonic or adult Raptor deletion, 
respectively (C57BL/6 background; embryonic Raptor deletion: n = 7 
controls, n = 20 Raptor deletion; adult Raptor deletion 2 months after 
doxycycline administration, n = 13 each, 6 months after doxycycline 
administration, n = 8 controls, n = 9 Raptor deletion; **P < 0.001). (F) 
Adult Raptor deletion on ICR background caused significant albumin-
uria (n = 14 controls, n = 19 Raptor deletion; **P < 0.001). Data are 
expressed as the mean ± SEM. (G) Histological analyses 6 months 
after podocyte-specific Raptor deletion (C57BL/6 background) docu-
menting glomerulosclerosis in embryonic induced mice. In adult doxy-
cycline-induced mice (C57BL/6 background), synechia, but no glomer-
ulosclerosis, could be detected (arrows indicate sclerosed glomeruli 
or synechia, respectively, arrowheads indicate proteinaceous casts in 
distal tubules). Scale bars: 20 μm.
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Strikingly, the combined podocyte-specific deletion of mTORC1 


















Podocyte-specific knockout of the mTORC2 complex results in reduced ability to adapt to stress. (A) Schematic illustration of the generation 
of podocyte-specific Rictor-deficient mice (RictorΔpodocyte) to interrupt mTORC2 signaling. (B) Western blot analysis of isolated glomeruli from 
RictorΔpodocyte mice confirmed the significant reduction of Rictor and pPKCε S729. (C) RictorΔpodocyte mice displayed no significant increase in 
albuminuria at 12 and 24 months of age (n = 6 control and n = 10 RictorΔpodocyte mice; 12 months, P = 0.11; 24 months, P = 0.24). (D–F) No obvi-
ous histological and ultrastructural lesions in 12-month-old RictorΔpodocyte mice. (G) RictorΔpodocyte mice exhibited a significantly increased transient 
albuminuria in the BSA overload model compared with control mice (n = 8 control and n = 8 RictorΔpodocyte mice; *P < 0.05). Scale bars: 20 μm 
(D); 2 μm (E, upper panel); 1 μm (E, lower panel); 10 μm (F, upper panel); 1 μm (F, lower panel). Data are expressed as the mean ± SEM.
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Figure 
Synergistic action of mTORC1 and mTORC2 complexes are required for glomerular homeostasis. (A) Schematic illustration of the genera-
tion of podocyte-specific Raptor- and Rictor-deficient mice (Raptor/RictorΔpodocyte) to interrupt mTORC1 and mTORC2 signaling. (B) Raptor/
RictorΔpodocyte developed an early onset massive albuminuria (n = 7 control and n = 6 Raptor/RictorΔpodocyte mice; **P < 0.01). (C and D) Rap-
tor/RictorΔpodocyte mice exhibited significant growth retardation after 5 weeks of age (n = 8 control and n = 6 Raptor/RictorΔpodocyte mice; *P < 0.05, 
**P < 0.01). (E) Histological analyses displayed glomerulosclerotic changes with circumferential synechia, crescent formation, vacuolization of 
podocytes, sometimes complete glomerular obsolescence, and proteinaceous casts in dilated distal tubules. Arrows indicate sclerotic glomeruli; 
asterisks indicate proteinaceous casts. (F) Raptor/RictorΔpodocyte mice showed global foot process effacement or loss of foot processes with 
denudation of the basement membrane in ultrastructural analyses (arrows depict foot process effacement; arrowhead indicates loss of foot 
processes). (G) Raptor/RictorΔpodocyte mice developed renal failure with increased serum creatinine (n = 9 control and n = 5 Raptor/RictorΔpodocyte 
mice; ***P < 0.0001) and (H) died between 6 and 12 weeks of age. Scale bars: 20 μm (E); 2 μm (F, upper panel); 1 μm (F, lower panel). Data 
are expressed as the mean ± SEM.
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Figure 
mTORC1 hyperactivation is a molecular signature of diabetic nephropathy. (A) Glomerular gene expression data of microdissected glomeruli 
from patients with glomerulopathies; very early diabetic nephropathy (diabetes; n = 22), MCD (n = 5), and controls (pretransplant allograft biop-
sies, LD, n = 18). mTOR/Raptor target gene expression was upregulated in diabetic nephropathy, but not in MCD. (B) Upregulation of pS6 in 
glomeruli of patients with diabetic nephropathy, but not in patients with MCD (arrows indicate pS6 signal). (C) Quantitative analysis of glomerular 
pS6-stained area in glomeruli of patients (n = 3 control, n = 5 for diabetes and minimal change; *P < 0.05, ***P < 0.0001). (D) Upregulation of pS6 
in podocytes of STZ-induced diabetic mice (arrows indicate podocytes). (E) Quantitative analysis of glomerular pS6-stained area in glomeruli of 
diabetic mice (n = 3 mice each). (F) Densitometric analysis after Western blotting of pS6 levels in glomerular lysates of control and STZ-injected 
diabetic mice (n = 4 mice each). Scale bars: 20 μm (B); 5 μm (D). Data are expressed as the mean ± SEM.
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Podocyte-specific genetic inhibition of mTOR hyperactivation pre-
vents progressive glomerular diseases. (A) Schematic illustration of 
the generation of podocyte-specific Raptor heterozygous knockout 
mice (RaptorHet podocyte mice) to counteract mTORC1 hyperactiva-
tion. (B) Glomerular Raptor and pS6 levels in RaptorHet podocyte mice. 
(C) Densitometric analysis of Raptor and pS6 levels (n = 3 mice). (D) 
Reduced S6 phosphorylation in podocytes of diabetic RaptorHet podocyte 
mice in the STZ model (arrows indicate pS6 signal in podocytes). (E) 
Quantitative analysis of glomerular pS6 stained area in glomeruli (n = 3 
mice each; **P < 0.001, ***P < 0.0001). (F) The RaptorHet podocyte gen-
otype ameliorated the development of proteinuria in the STZ model 
(n = 11 control and n = 5 RaptorHet podocyte mice; *P < 0.05). (G) His-
tological analysis revealed reduced glomerulosclerosis and reduced 
mesangial matrix expansion in RaptorHet podocyte mice exposed to STZ 
(arrow indicates sclerosed glomerulus). (H) Glomerulosclerosis index 
(24) documenting ameliorated diabetic nephropathy in RaptorHet podocyte 
mice (n = 3 each; *P < 0.05) (I) There was a significant increase in 
glomerular mean mesangial volume in WT animals compared with 
RaptorHet podocyte mice after diabetes induction, with no significant dif-
ference in mean glomerular volume (n = 3 each; *P < 0.05). (J) Quanti-
tative stereological analyses displayed a significantly increased mean 
podocyte volume in WT animals compared with RaptorHet podocyte mice 
after diabetes induction, with no significant difference in the number of 
podocytes per glomerulus (n = 3 each; *P < 0.05). (K) Ultrastructural 
analysis displayed increased podocyte volume in WT animals in the 
STZ model (arrows indicate podocytes; arrowhead indicates mesan-
gial matrix expansion). Scale bars: 5 μm (D); 20 μm (G); 5 μm (K). 
Data are expressed as the mean ± SEM.
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